MYNZEPLI 40 mg/ml, solution for injection in a vial bottle, 0.1 ml
Active ingredients: Aflibercept
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 0.1 mlintravitréenne
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MYNZEPLI 40 mg/ml, solution injectable en flacon
- Pharmaceutical form
- solution injectable
- Route of administration
- intravitréenne
- Presentation description
- 1 flacon(s) en verre de 0,1 ml avec aiguille(s) filtre(s)
- Marketing authorisation holder
- ADVANZ PHARMA LIMITED
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 May 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65318552CIP73032594CIP133400930325940Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| AFLIBERCEPTsolution | 40 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.